Abstract. Antiangiogenic therapy, as a new anticancer method, can improve the anticancer effect of traditional therapies. Different antiangiogenic drugs may have different vascular normalization time windows. Whether the antiangiogenic treatment is within the vascular normalization time window is very important in the treatment of cancers. Previous studies have indicated that recombinant human endostatin (rh-ES) can transiently normalize tumor microvessels. Yet the molecular mechanism and the time window of rh-ES remains unclear. The aim of the present study was to explore the optimal time window and molecular mechanism of rh-ES in inhibiting Lewis lung cancer (LLC). By comparatively accessing the changes in microvascular and hypoxic conditions of tumors in host mice treated with rh-ES or saline for different days, the authors aimed to investigate the best administration time of rh-ES treatment on human lung cancers and obtain a better understanding concerning the involved molecular mechanism. A total of 40 C57/BL6 mice with LLC xenografts were randomly divided into normal saline (NS) and rh-ES groups (20 mice/group). 0.2 ml NS or 5 mg/kg rh-ES were administrated via intraperitoneal injection (i.p.) into each mouse each day during the 9-day experiment. A total of 5 mice from each group were sacrificed at day 2, 4, 6 or 9. CA9 and RGS5 expression levels of both groups were compared using immunohistochemistry, reverse transcription-quantitative polymerase chain reaction and ELISA. Rh-ES caused vascular normalization and improved hypoxia at days 4 and 6. Compared with the control (NS) group, both CA9 and RGS5 expression in rh-ES group were significantly decreased at days 4 and 6 (P<0.05), while no significant change between two groups was observed at days 2 and 9. Rh-ES can induce transient tumor vascular normalization and improves tissue hypoxia in LLC tumors. The vascular normalization window is accompanied by the reduction in RGS5 and CA expression.
Introduction
Previously, it was believed that antiangiogenic drugs inhibit tumors by promoting degradation of tumor blood vessels, causing ischemia and hypoxia in the tumor, leading to tumor cell death (1) . According to this theory, anti-angiogenic drugs would antagonize the effect of other cancer treatments, such as chemotherapy, because the lack of oxygen and blood supply impedes the delivery of other drugs. However, the truth is that the antiangiogenic drugs actually enhance the efficacy of radiotherapy and chemotherapy. Therefore, antiangiogenic drugs may inhibit tumors by some other mechanisms. In 2004, Lin and Sessa (2) first proposed the 'time window' concept for tumor angiogenesis. They believed that there is a certain period, during which antiangiogenic drugs have the greatest anti-tumor effect. In this time window, the newly formed tumor vessels tended to be normal in vascular endothelial maturation, morphological regulation and tight junctions, and thus, anticancer drugs can easily reach the tumor cells, directly damaging tumor cell DNA and inhibiting vascular endothelial cell proliferation. The time window of tumor vessel normalization is specifically marked by improved tumor hypoxic status and change in pericyte coverage (1, 3) . Generally, pericytes in the tumor vascular bed display obviously abnormal structure and the pericyte coverage is low (4) . Pericyte maturation and blood vessel normalization take place following the deplethe deplethe depletion of regulator of G-protein signaling 5 (RGS5), one of the proteins that reflects pericyte coverage (5, 6) . Hypoxia, a common phenomenon in human tumors (7) , can cause tumors to become resistant to therapy and lead to tumor progression (8) . Carbonic anhydrase 9 (CA9), a transmembrane zinc metalloenzyme, can be induced by hypoxia and promoting aggressive behaviors of tumors by helping maintain normal intracellular pH and preventing apoptosis in a hypoxic environment (9) .
Antiangiogenic effects of recombinant human endostatin in lung cancers
Endostatin is the 20 kDa c-terminal fragment of collagen XVIII that is primarily located in the baseis primarily located in the baseis primarily located in the baselocated in the baselocated in the basement membrane of blood vessels. It was first described by O'Reilly et al (10) in 1997 and was licensed by EntreMed. In spite of the fact that preclinical and clinical studies on tumor suppression were very positive, EntreMed abandoned phase III clinical trials due to an insufficient supply of endostatin. Nevertheless, endostatin development was continued by scientists in China and recombinant human endostatin (rh-ES, with the trade name Endostar) has been approved by the China Food and Drug Administration. The use of it in combination with chemotherapy has been suggested by the National Comprehensive Cancer Network (NCCN) Guidelines to treat non-small cell lung cancer (NSCLC). However, the optimal administration time of rh-ES and its molecular mechanism still remain unclear. In the current study, by using a Lewis lung cancer (LLC) tumor model, the authors aimed to identify the optimal administration time of rh-ES in cancer treatment and its possible molecular mechaand its possible molecular mechaand its possible molecular mechanism.
Materials and methods
Ethical statement. The present study was approved by the Ethics Committee of North Sichuan Medical College (Nanchang, China).
Cell culture and animal model. Mouse LLC tumor cells were purchased from the State Key Laboratory of Cancer Biotherapy at Sichuan University (Chengdu, China). The 6-8 week-old female mice with a body weight of 15-20 g were purchased from the Laboratory Animal Center of North Sichuan Medical College (Nanchong, China). LLC cells at logarithmic growth phase were collected as a 1x10 6 cells/ml single cell suspension. Cells (0.2 ml) were injected subcutaneously into the left armpit of each C57/BL6 mouse. The growth and tumor formation in the mice was observed and recorded.
Animal treatment and tumor sample collection. Treatment started when the LLC tumors reached a diameter of 6 mm. A total of 40 mice were randomly split into two equal groups: NS and rh-ES. Mice in the NS group were intraperitoneally injected with 0.2 ml 0.9% normal saline daily for up to 9 days, while mice in rh-ES group were intraperitoneally injected with 5 mg/kg rh-ES (Shandong Simcere-Medgenn Bio-Pharmaceutical Co., Ltd., Yantai, China) daily for up to 9 days. A total of 5 mice from each group were sacrificed at days 2, 4, 6 and 9 following treatment. Each tumor sample was split into two parts. One part was snap-frozen within 30 min following animal sacrifice and stored at -80˚C for further RNA and protein analyses. The other part was fixed with 4% paraformaldehyde and dehydrated, and embedded in paraffin for immunohistochemical analysis.
Immunohistochemistry (IHC). Sections (5 µm) were prepared from paraformaldehyde-fixed, paraffin-embedded tissues and were used for immunocytochemistry. The CD31 antibody (cat no. ab28364; dilution, 1:500) was obtained from Abcam (Cambridge, MA, USA) and incubated at 37˚C for 2 h. RGS5 (cat no. ab138019; Abcam, Shanghai, China) and CA9 (cat no. NB100-417; Novus Biologicals, LLC, Littleton, CO, USA) antibodies were used at a 1:100 dilution at 37˚C for 2 h. The bound antibody was visualized with SABC IHC kit (Santa Cruz Biotechnology, Inc., Dallas, TX, USA). The positive RGS5 signal was located in the cytoplasm and had a color of light yellow to brown, while the CA9 signal was located on the cell membrane and had a color of brown. The authors followed the criteria used by Rahman et al (11) 
Reverse transcription-quantitative polymerase chain reacpolymerase chain reacpolymerase chain reaction (RT-qPCR).
Total RNA samples were extracted from tissues using Total RNA extraction kit (Omega Bio-Tek, Inc., Norcross, GA, USA). cDNA samples were synthesized using a cDNA synthesis kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA) (42˚C, 60 min; 70˚C, 5 min) and the cDNA used for RT-qPCR (Stage 1: 95˚C, 30 sec; Stage 2: 95˚C, 5 sec; 60˚C, 34 sec; repeated 40 times. Stage 3: 95˚C, 15 sec; 60˚C, 60 sec and 95˚C, 15 sec). Primers were purchased from Shanghai Generay Biotech Co., Ltd. (Shanghai, China). Sequences are as follows: GAPDH forward, 5'-AGA AGG TGG TGA AGC AGG CATC-3' and reverse, 5'-CGA AGG TGG AAG AGT GCG AGTTG-3'; RGS5 forward, 5'-ATC AAA ATG GCG GAG AAG GCAAA-3' and reverse, 5'-CAC AAA GCG GGG CAG AGA ATC-3'; CA9 forward, 5'-TGT GGG GAC CTC GTG ATT CTCG-3' and reverse, 5'-TGG ACT GGC TCA GGG CTG CTAT-3'. The relative levels of gene expression were quantified by using the comparative Cq method (12) .
ELISA. Tumor tissues were homogenized using 1X cell lysis buffer (cat no. 9803; Cell Signaling Technology, Inc., Danvers, MA, USA) and centrifuged at -4˚C and 12,000 x g for 15 min.
The supernatant was harvested and tested using ELISA kits (cat nos. MBS2604739 and MBS939749; MyBiosource, Inc., San Diego, CA, USA) for RGS5 and CA9 following manufacturer's protocols. A total volume of 100 µl blank, standards, and tumor samples were added into wells. Optical density was measured at 450 nm. Results are expressed as ng/ml of homogenizing buffer.
Statistics. Data are presented as the mean ± standard deviation. The significance between two groups was tested using Student's t-test (two tailed) and P<0.05 was considered to indicate a statistically significant difference. SPSS software (version, 13.0; SPSS, Inc., Chicago, IL, USA) was used for statistical analysis.
Results

LLC tumor formation.
The tumor formation rate in C57/BL6 female mice was 100%. On day 10, following subcutaneous injection of LLC cells, tumor xenografts grew to a size of ~6 mm in diameter. The tumors were hard and spherical, and displayed poor activity and expansive growth.
Rh-ES causes transient LLC tumor vascular normalization and improves tumor tissue hypoxia.
To examine the changes in tumor vascularization, the authors performed immunohistochemical staining for CD31, a microvessel marker, on LLC tumors treated with rh-ES for 2, 4, 6 and 9 days. It was reported that LLC tumors treated with rh-ES for 4 or 6 days presented lower CD31 expression than those treated for 2 or 9 days. The authors calculated microvessel density as a ratio of microvessel number to the area of the image to measure CD31 immunoreactivity. The data indicated a significant reduction in the vascularity of the LLC tumor xenografts following treatment with rh-ES for 4 or 6 days. In contrast, no significant change was observed for LLC tumors treated with rh-ES for 2 days or 9 days ( Fig. 1 and Table I ).
Immunohistochemical analysis demonstrates the reduction of RGS5 and CA9 protein expression in tumor cells at d4 and d6 of treatment, but not at d2 and d9. RGS5 is a master regulator for tumor vascular normalization. CA9 is a biomarker of tumor hypoxia. To test whether rh-ES can cause a change in the expression of these two proteins, using immunohistochemical analysis, the authors examined the RGS5 and CA9 protein expression levels in LLC tumors treated with rh-ES or saline for 2, 4, 6 and 9 days. It was determined that, compared with the NS group, both RGS5 and CA9 levels in rh-ES group were significantly lower at days 4 and 6 (P<0.05), while there was no significant change between two groups at days 2 and 9 (Figs. 2-5 and Tables II and III) .
RT-qPCR analysis demonstrates a reduction of RGS5 and CA9 mRNA levels in tumor cells at days 4 and 6 of treatment, but not at days 2 and 9. To confirm that rh-ES can cause a reduction in the expression of RGS5 and CA9, the authors performed RT-qPCR on LLC tumors of NS and rh-ES groups. Compared with the NS group, both RGS5 and CA9mRNA levels in the rh-ES group were significantly lower at days 4 and 6 (P<0.05), while there was no significant change between two groups at days 2 and 9 (Figs. 6 and 7).
ELISA further confirms the reduction of RGS5 and CA9 protein levels in tumor cells at days 4 and 6 of treatment, but not at days 2 and 9.
To further confirm the effect of rh-ES, ELISA was performed on LLC tumors of NS and rh-ES groups. Compared with the NS group, both RGS5 and CA9 protein levels in rh-ES group were significantly lower at days 4 and 6 (P<0.05), while there was no significant change between two groups at days 2 and 9 (Figs. 8 and 9
and Tables IV and V) .
Discussion
The use of rh-ES as an antiangiogenic drug in advanced NSCLC has been suggested by the Chinese version of the NCCN guidelines (13) . Besides lung cancer (14), studies and clinical trials have demonstrated the anticancer effect of rh-ES in other cancers such as melanoma, nasopharyngeal and esophageal cancer (15) (16) (17) . These studies have reported that rh-ES can cause transient normalization of tumor vasculature. Consistent with previous studies, using an LLC tumor model, the authors demonstrated that the reduction of microvessel marker CD31 caused by rh-ES occurs between days 4 and 6 following the start of rh-ES treatment, and is reversed at day 9 or even earlier, demonstrating that the vascular normalization of LLC tumors caused by rh-ES is transient and reversible. Based on the 'vascular normalization window' hypothesis proposed by Jain (3), the time window ranging from day 4 to day 6 would be the best scheduling time for a combination therapy using rh-ES and chemo-or radio-therapy. In the past decade, vast evidence has emerged in support of the 'normalization window' hypothesis for tumor angiogenesis. Molecular mechanisms have been investigated to understand this process. Among these mechanisms, VEGF is demonstrated to be a key regulator for angiogenesis. Although there is no doubt concerning the anti-angiogenic effect of rh-ES, the molecular mechanism for this effect still remains unclear. Different research groups have demonstrated that rh-ES can reduce the expression levels of vascular endothelial growth factor (VEGF), indicating that VEGF may play an important role in rh-ES-induced vascular normalization (14, 16) . Aside from this, the general understanding of the effect of rh-ES has been limited. The current findings reported that RGS5 and CA9 were reduced by rh-ES during the 'vascular normalization window' are striking. To the best of the authors' knowledge, this is the first direct evidence to present the roles of RGS5 and CA9 in the antiangiogenic effect of rh-ES.
Rgs5 has been identified as a master gene responsible for the abnormal vasculature in mouse tumors. Loss of Rgs5 can cause vascular normalization and a consequent reduction in tumor hypoxia and vessel leakiness, leading to enhanced influx of immune effector cells into the tumor (18) . However, the relationship between RGS5 and VEGF is not completely understood. On one hand, RGS5 can be triggered by tumor vasculature and sustained by VEGF-rich proangiogenic microenvironment (19) . One the other hand, RGS5 can antagonize the angiogenic effect of VEGF through the p38 signaling pathway (20) . Whether the reduction of RGS5 by rh-ES is mediated by VEGF or is independent of VEGF needs to be further investigated. The presented tumor model provides the best in vivo system for such a follow-up study to better the understanding of the molecular mechanism involved in the anti-angiogenic effect of rh-ES.
Different to RGS5, the relationship between CA9 and VEGF is clearer. The regulation of CA9 is differential from the regulation of VEGF in hypoxic conditions, which has been demonstrated in bladder cancer (21) . By using this system, the authors will be able to examine whether the rh-ES-induced CA9 reduction is independently of VEGF in future studies.
In conclusion, the authors have provided evidence that rh-ES can cause transient and reversible tumor vascular normalization, optimizing the schedule of combination therapy in human tumors. Most importantly, the novel findings that the expression of RGS5 and CA9 is reduced during the 'vascular normalization window' suggested that RGS5 and CA9 may be used as biomarkers for defining the 'vascular normalization window'.
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